Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Yale-New Haven plans neuroscience center

Yale-New Haven Hospital has unveiled plans to build up its St. Raphael campus with a 505,000-square foot, $838 million neuroscience center for research and treatment...

| By Bill Kelly

BioCT welcomes new member KPMG

KPMG LLP provides tax, audit and advisory services (including strategy, risk, regulatory and M&A) to over 500 life sciences clients in the northeast region. The...

| By Bill Kelly

JAX studies structural variants in human genome

A paper published in Nature Communications delves deeper into individual genomic differences than ever before. The work involved a large international team of researchers from the...

| By Bill Kelly

Alexion gets positive opinion from European agency

Alexion Pharmaceuticals reports that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS®...

| By Bill Kelly

Yale professor receives CASE science medal

The Connecticut Academy of Science and Engineering has announced that Yale School of Medicine professor Pasko Rakic is the 2019 recipient of the Connecticut Medal...

| By Bill Kelly

Hartford partners to launch medtech accelerator

Hartford HealthCare, Trinity College and the UConn School of Business are planning the launch a medical technology and digital health accelerator, which would join insurance...

| By Bill Kelly

BioXcel Therapeutics blooms in New Haven

Twelve stories above New Haven Harbor, BioXcel Therapeutics is using Big Data technology to mine Big Pharma chemistry and create new drugs that treat pancreatic cancer...

| By Bill Kelly

UConn spearheads animal vaccine, ADHD research

The U.S. Department of Agriculture National Institute of Food and Agriculture has designated UConn’s CEVR (Center of Excellence for Vaccine Research) to be the National Center...

| By Bill Kelly

Intensity gets FDA Fast Track for breast cancer drug

Intensity Therapeutics has received an FDA Fast Track designation for its INT230-6 for the treatment of patients with relapsed or metastatic triple negative breast cancer (TNBC)...